The Cancer Gold Rush Threatening America’s Seniors

Big Pharma’s next cancer gold rush is here.

And this one could empty your wallet… and actually GIVE you cancer instead of preventing it.

It sounds crazy… but it’s true.

For decades, mainstream medicine has ignored obesity as one of the largest risk factors for cancer, even though the science was undeniable.

But over the past several months, something has changed…

In June, the U.S. Centers for Disease Control and Prevention issued a new warning on the obesity-cancer link.

Good Morning America did a whole segment on obesity and cancer… and other news outlets followed suit.

Why the sudden interest?

We’re being set up for the biggest drug company gold rush since cholesterol-lowering statins.

And this is one cash grab that could put you and millions of other Americans at risk.

Talk about the mother of all coincidences…

Government agencies heavily influenced by the drug companies… and media outlets that reap fortunes in drug company advertising… are suddenly interested in the connection between obesity and cancer…

At the same exact time that blockbuster GLP-1 weight loss drugs are being studied for cancer prevention.

That’s right… there’s research pouring in from around the world right now trying to prove that GLP-1 drugs lower cancer risk by helping you lose weight and improve your blood sugar.

Colon cancer… breast cancer… immune pathways for stopping cancer. They’re studying it all.

And of course they are… this is a market worth hundreds of billions of dollars. If they could get millions of Americans on a $1,000-a-month shot for cancer prevention, the profits would be enormous.

It would sound crazy if it hadn’t happened before.

Remember the scare tactics and media frenzy about cholesterol that ramped up in the 1980s… right before statins magically appeared?

Of course, the real irony here is that some GLP-1 drugs like Ozempic and Wegovy actually carry black-box warnings that they could increase your risk of thyroid cancer.

This is right from the Ozempic website:

Ozempic® may cause serious side effects, including: Possible thyroid tumors, including cancer.

Friend, this is one Big Pharma gold rush you want no part of.

Here’s the truth… being overweight has always been a major risk factor for cancer. Fat cells pump out hormonal signals that:

• push tumors into “growth mode”
• help cancer cells resist death
• send out inflammatory sparks that damage DNA
• and create the perfect environment for mutations

But, despite the sudden interest from the government, media, and drug companies, you don’t need a $1,000 injection to calm insulin, shrink inflammation, or improve metabolic health.

Prioritizing real, protein-rich meals steadies insulin. Going 12–14 hours overnight without food lets your metabolism reset.

Natural compounds like berberine, curcumin, and EGCG support the same metabolic pathways GLP-1 drugs manipulate—without the cost, rebound, or muscle loss.

These simple, natural solutions make a whole lot more sense than a budget-busting drug you stay on for life.

To lowering your risk — naturally and on your own terms,

Rachel Mace
Managing Editorial Director, e-Alert
with contributions from the research team

P.S. Cancer breakthrough accidentally discovered by cattle farmers?

Sources:

• Mahamat-Saleh, Y., et al. (2024). Association of metabolic obesity phenotypes with risk of several cancers: a Mendelian randomization and cohort analysis. British Journal of Cancer, 130, 240–253. https://doi.org/10.1038/s41416-024-02857-7
  https://www.nature.com/articles/s41416-024-02857-7
• Wang, L., et al. (2024). Glucagon-like peptide 1 receptor agonists and risk of 13 obesity-associated cancers: a retrospective cohort study of 1.65 million patients with type 2 diabetes. JAMA Network Open, 7(4), e2820833. https://doi.org/10.1001/jamanetworkopen.2024.20833
  https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2820833
• Rubinstein, M. M., et al. (2021). Targeting obesity-related dysfunction in hormonally driven cancers. British Journal of Cancer, 124, 1267–1276. https://doi.org/10.1038/s41416-021-01393-y
  https://www.nature.com/articles/s41416-021-01393-y
• Karra, P., et al. (2022). Metabolic dysfunction and obesity-related cancer: results from the International Center for Health and Science. Cancer Medicine, 11(9), 3018–3029. https://doi.org/10.1002/cam4.4912
  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9302704/
• Doerstling, S. S., et al. (2017). Obesity and cancer metabolism: a perspective on interacting signalling and pathways. Obesity Reviews, 18(4), 451–466. https://doi.org/10.1111/obr.12535
  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604081/
• Font-Burgada, J., Sun, B., Karin, M. (2016). Obesity and cancer: the oil that feeds the flame. Cell Metabolism, 23(1), 48–62. https://doi.org/10.1016/j.cmet.2015.12.010
  https://www.cell.com/cell-metabolism/fulltext/S1550-4131(15)00630-0 Cell
• Silverii, G. A., et al. (2023). GLP-1 receptor agonists and the risk for cancer: a meta-analysis. Diabetes, Obesity and Metabolism, 25(10), 2118–2128. https://doi.org/10.1111/dom.16489
  https://onlinelibrary.wiley.com/doi/10.1111/dom.16489 Wiley Online Library
• Valencia-Rincón, E., et al. (2025). GLP-1 receptor agonists and cancer: current clinical evidence from pre-clinical and clinical studies. Frontiers in Oncology, 15, 132456. https://doi.org/10.3389/fonc.2025.132456